Investors |

Financial Information

Stock listing: The company’s common shares are listed and traded on the OTCQB Venture Market in the United States under the symbol LXXGF, and in Canada on the TSX Venture Exchange under the symbol LXG.

Currency: LexeGene reports its financial results in Canadian dollars, which is the functional currency of the company.

Share Structure and Capital

As of 13 March 2017 
Shares Outstanding49,460,423
Warrants Outstanding11,246,363

Options - To be granted
(Ave. Price $0.34 CAD)
2,175,000

Fully Diluted Market Capital
(62,881,786 Shares @ $0.78 CAD)
$49.0 M CAD

Treasury
$2.8 M CAD

Financials

2016 Downloads
Financial Statements for the period ending November 30, 2016
Management Discussion and Analysis for the period ending November 30, 2016
Financial Statements for the period ending September 30, 2016
Management Discussion and Analysis for the period ending September 30, 2016
Financial Statements for the period ending June 30, 2016
Management Discussion and Analysis for the period ending June 30, 2016
Financial Statements for the period ending March 31, 2016
Management Discussion and Analysis for the period ending March 31, 2016

2017 Downloads
Financial Statements for the period ending February 28, 2017
Management Discussion and Analysis for the period ending February 28, 2017

Investor inquiries

Daryl Rebeck |  President, LexaGene
T: 1.800.215.1824
E: darylrebeck@lexagene.com

Auditors

Dale Matheson Carr-Hilton Labonte LLP
1500 – 1140 West Pender St.
Vancouver, BC
Canada V6E 4G1

Attorneys

McMillan LLP
Royal Centre, 1055 West Georgia Street
Suite 1500, PO Box 11117
Vancouver, BC
Canada V6E 4N7
Contact: Desmond Balakrishnan

Transfer agent

Computershare Investor Services Inc.